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                     Introduction 
INTRODUCTION 
    In the ancient times, people obtained medicines to cure illness from nature. The rising number of diseases 
and the emergence of resistance to established therapies gradually raised the need for the discovery and 
development of new drug moieties. 
   This thesis deals on the synthesis, characterization and screening of some novel Cinnoline derivatives. This 
chapter deals with the importance of heterocyclic compounds, chemistry of Cinnoline and brief introduction 
to therapeutic activity based on the ring. A literature survey on the investigation carried out by earlier 
workers on this ring moiety is also included in this chapter. 
               Medicinal chemists1-2 has stimulated by the need of sick for drugs, have made some of the proudest 
and most spectacular achievements of contributing therapeutic agents. It have been started that ‘Medicinal 
chemistry’ concerns the discovery, the development, identification and interpretation, mode of action of 
biologically active compounds at the molecular level. The primary objective of medicinal chemistry is the 
design and discovery of new moieties that are suitable for use as drugs. The discovery of a new drug 
involves not only its design and synthesis but also to establish how a new drug entity elicits its action into 
the body. Drug discovery may also require fundamental research into the biological and chemical nature of 
the diseased state. 
              The knowledge required by a medicinal chemist is both a challenge and a reward. His work is 
centered on the discovery of new molecular soldiers to win the battle against disease. It includes the 
development of more effective and safer analogues from both, new and existing lead compounds. This 
usually involves synthesizing and testing many hundreds of compounds before a suitable compound is 
produced. 
             Heterocyclic rings3-6, which have been reason for the activity of most of the drugs of natural origin 
leads to the discovery of many synthetic drugs possessing the heterocyclic rings and their fused analogs 
represent an important class of heterocyclic compounds exists in numerous natural products displaying a 
wide range of biological and pharmaceutical activities. On intensive research heterocyclic derivaties 
continue to yield new medicinal agents. 
           MALARIA56 is a mosquito borne infectious disease caused by a eukaryotic protest of genus 
Plasmodium. It have been one of the greatest burdens to mankind, with a mortality rate which is unmatched 
by any other modern diseases, this is the major health problem in most of the countries in the tropics. 
Malaria affects more than 2400 million people, over 40% of the world’s population, in more than 100 
countries in the tropics from South America to Indian peninsula. The tropics provides an ideal breeding and 
living conditions of the anopheles mosquito, and hence this distribution. Over the years, as per statistical 
records, it have been estimated that there may be 300 to 500 million new infection and 1 to 3 million 
infection related to the deaths annually caused by malaria, and it have also been found that more than 90% of 
the deaths occur in the regions in and around Sub-Saharan Africa. Malaria kills in 1 year what AIDS killed 
in 155 year, if 5 million people have died of AIDS, 50 million people have died of malaria. 
           Yet, in this age of tremendous technological and medical advancements, its a big surprise that human 
knowledge power have not been able to control this disease, if not eradicate it. The intolerable impact of 
malaria have been sometimes fully or partially attributed to their increasing resistance of the Plasmodium 
parasite to chemoprophylactic and chemotherapeutic agents, and their resistance of the Anopheles species 
mosquito vector to insecticides, including the pyrethroids used in insecticide impregnated bednets. Adding to 
these its the inability of health, public and civil work departments of the affected countries in mobilizing and 
sustaining the resources required to malarial control. 
Malaria is caused by Plasmodium parasites57, 58: 
              Malaria is one of the most widespread infectious diseases of our time; it belongs to the genus 
Plasmodium. There are five species of the protozoan parasites which infect humans. Malaria is caused by the 
Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium 
knowlesi. 
Life cycle of the malarial parasite: 
             The life cycle of the malarial parasite is complicated, which involves two hosts, human and 
Anopheles mosquito. Plasmodium falciparum and, to a much lesser extent, P.vivax are the main causes of 
disease and death due to malaria. 
 
• A female Anopheles mosquito carrying malaria causing parasites feeds on human and injects the 
parasites in the form of sporozoites into their blood stream. The sporozoites travel in to their liver 
and invade liver cells.  
• Over 5-16 days, their sporozoites grow, divide, which produce tens of thousands of haploid forms 
called merozoites, perliver cell. Some malarial parasite species remains dormant for extended 
periods to the liver, causing relapses weeks or months later. 
• The merozoites exit in their liver cells and re-enter the blood stream, beginning the cycle for the 
invasion of the red blood cells, asexual replication, and release of newly formed merozoites from the 
red blood cells repeatedly over 1-3 days. This multiplication can result in the thousands of parasite-
infected cells in their host blood stream, leading to illness and complications of malaria that can last 
for months if not treated. 
• Some of their merozoites infected blood cells leave the cycle for asexual multiplication. Instead of 
replicating, the merozoites in these cells develop into sexual forms of the parasite, called male and 
female gametocytes which are circulate in to their blood stream. 
• When a mosquito bites an infected human, it ingests the gametocytes. In the mosquito gut, the 
infected human blood cells burst, releasing the gametocytes, which develops further into the mature 
sex cells called gametes. Male and female gametes fuse to form the diploid zygotes, which develop 
into the actively moving ookinetes that burrow into the mosquito midgut wall and form oocysts.    
• Growth and division of each oocyst produces thousands of active haploid forms called sporozoites. 
After 8-15 days, the oocyst bursts, releasing sporozoites into the body cavity of the mosquito, from 
which they travel into and invade the mosquito salivary glands. The cycles of human infection re-
starts when the mosquito takes a blood meal, injecting their sporozoites from its salivary glands into 
the blood stream. 
Symptoms of malaria59: 
 
Malaria is generally characterized by recurrent attacks, each of which occurs in three stages. Moderate to 
severe shaking chills (cold stage) followed by high fever (hot stage), and then profuse sweating the body 
temperature falls (sweating stage); the classical malarial attacks lasts for 6-10 hours. Along with chills, the 
person is likely to have fever and flu like symptoms, such as chills, headache, muscle aches, tiredness, 
nausea, vomiting and diarrhoea. Malaria can also cause anaemia and jaundice due to loss of red blood cells. 
Malarial signs and symptoms60 typically begins within the few weeks (10-16 days) after a bite from an 
infected mosquito. However, some types of malarial parasites can lie dormant in your body for months, or 
even years. 
Diagnosis61: 
   The diagnosis of malaria is confirmed by the blood tests which can be divided into microscopic and non-
microscopic tests. 
¾ Microscopic tests involve staining and direct visualization of the parasite under the microscope. 
• Peripheral Smear study- MP test                                                                                 
• Quantitative Buffy coat (QBC) test 
¾ Non-Microscopic tests involve the identification of the parasitic antigen or the antiplasmodial 
antibodies or the parasitic metabolic products. 
• Rapid Diagnostic tests (RDTS) 
TUBERCULOSIS: 
          Tuberculosis (TB) is an infectious disease caused by the bacteria whose scientific name is 
Mycobacterium tuberculosis. It was first isolated in 1882 by a German physician named Robert Koch who 
received the Nobel Prize for this discovery. It affects62 32% of the human population and it causes 1.8 
million of deaths annually. As per WHO estimates, 9 million people globally develop active TB and 1.7 
million people die annually. (TB) the most commonly affects the lungs but also it can involve almost any 
organs of the body. Many years ago, this disease was referred to as ‘consumtion’ because without effective 
treatment, those patients often would waste away. Today of course, tuberculosis was usually can be treated 
successfully with the antibiotics. 
            From the chemotherapeutic point of view63, there are two sources of new chemical entities. The first 
is the extraordinary diversity provided by the natural products. The second results from the design of new or 
the modernization of synthetic transformations. Although many compounds are in clinical trials, it is 
astonishing that with these backgrounds, there had been no new drugs registered to treat TB in the last 40 
years. This reflects that the inherent difficulties for discovery and clinical testing of new agents and the lack 
of pharmaceutical industry research in this area. 
           In terms of organ development, tuberculosis is often divided into pulmonary (respiratory) and extra 
pulmonary (non respiratory) types. The later should only be applied by organ involvement, which is 
secondary to a pulmonary lesion. If the disease does not involve the lung, it is referred to as the non-
pulmonary. 
Causative Organism: 
           Tuberculosis64 is an infection caused by the rod-shaped, non-spore forming, aerobic bacterium 
Mycobacterium tuberculosis. Mycobacteria typically measures upto 0.5 µm to 3 µm, which are classified to 
as acid-fast bacilli, and have a unique cell wall structure crucial to their survival. The well developed cell 
wall contains a considerable amount of the fatty acids, mycolic acid, covalently attached to their underlying 
peptidoglycan bound polysaccharide arabinogalactan, providing an extraordinary lipid barrier. This barrier is 
responsible for the many of the medically challenging physiological characteristics of tuberculosis, including 
resistance to antibiotics and with the host defence mechanisms. The composition and quantity of their cell 
wall components affects the bacteria’s virulence and growth rate. 
       The M.tuberculosis complex65 includes other TB causing mycobacteria they are M.bovis, M.africanum, 
M.canetti, M.microti.TB  other known pathogenic mycobacteria include M.leprae, M.avium, and M.kansasii. 
Mechanism66: 
           TB infection begins with when the mycobacterium reaches the pulmonary alveoli, where they invade 
and replicate within the endosomes of the alveolar macrophages. The primary site of infection to the lungs is 
called the ghon focus, and it is generally located in either the upper part of the lower lobe. Bacteria are 
picked up by dentritic cells, which do not allow replication, although these cells can transport the bacilli to 
their local lymph nodes. Further spread is through their blood stream to the other tissues and organs where 
the secondary tuberculosis lesions can develop in other parts of the lung, peripheral lymph nodes, kidneys, 
brain and bone. The severe form of tuberculosis disease was most common in infants and elderly and it is 
called military tuberculosis. If it’s untreated, infection with Mycobacterium tuberculosis would become 
lobar pneumonia. 
Pathophysiology67-73: 
         Once inhaled, the infectious droplets settled throughout their airways. The majority of the bacilli are 
trapped in the upper parts of the airways where their mucus secreting goblet cells exist. The mucus produced 
catches foreign substances, and their cilia on the surface of the cells constantly beat the mucus and its 
entrapped particles upward for its removal. This system provides the body with an initial physical defense, 
which prevents the infection in most persons exposed to tuberculosis. 
           Bacteria in droplets that bypass the mucociliary system and reach the alveoli are quickly surrounded 
and engulfed by alveolar macrophages, the most abundant immune effector cells which are present in the 
alveolar spaces. These macrophages, the next line of the host defense, are the part of the innate immune 
system and provide an opportunity for the body to destroy the invading mycobacteria and prevent infection. 
Macrophages are readily available phagocytic cells that combat many pathogens without requiring previous 
exposure to the pathogens. The complement system also plays a major role in the phagocytosis of the 
bacteria. The complement protein C3 binds to the cell wall which enhances recognition of mycobacteria by 
macrophages. Opsonization by C3 is rapid, even in the air spaces of a host with no previous exposure to 
Mycobacterium tuberculosis. 
           After being ingested by macrophages, the mycobacteria continue to multiply slowly, with their 
bacterial cell division occurring every 25 to 32 hours. Regardless of whether the infection becomes 
controlled or progresses, initial development involves the production of proteolytic enzymes and cytokines 
by macrophages in an attempt to degrade their bacteria. Released cytokines attract the T-lymphocytes in to 
their site, the cells that constitute the cell-mediated immunity. Macrophages then present mycobacterial 
antigens to their surface of the T cells. This initial immune process continues for 2 to 12 weeks, then the 
microorganisms continues to grow until they reach sufficient numbers to fully elicit the cell-mediated 
immune response, which can be detected by a skin test.  
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           According to their clinical utility, anti-tuberculosis drugs can be divided into, 
First line drugs: 
             These drugs have high anti-tuberculosis efficacy as well as low toxicity. 
1. Isoniazid (H) 2. Rifampin (R) 3. Pyrazinamide (z) 4. Ethambutol (E) 5. Streptomycin (S) 
Second line drugs: 
             These drugs have either low anti-tuberculosis efficacy or high toxicity or both. These are used for 
the special circumstances only. 
1. Thiacetazone (Tzn) 2. Para amino salicylic acid (PAS) 3. Ethionamide (Etm) 4. Cycloserine (Cys) 
5. Kanamycin (Kmc) 6. Amikacin (Am) 7. Capreomycin (cpr) 
Newer drugs: 
1. Ciprofloxacin 2. Oflaxacin 3. Clarithromycin 4. Azithromycin 5. Rifabutin  
Short Course Chemotherapy: 
              These are the regimens of 6-9 months duration which has been found to be highly efficacious. All 
regimens have an initial intensive phase lasting 2-3 months aimed to rapidly kill the bacilli, bring about 
sputum conversion and afford symptom relief. This is followed by a continuation phase lasting 4-6 months 
during which the remaining bacilli are eliminated so that relapse does not occur. 
Diagnosis76: 
• Tuberculin skin test (Mantoux test) . 
• Physical examination, a chest X-ray, microbiological smears, and cultures. 
• Mycobacterium tuberculosis (stained red) in the sputum. 
• Polymerase chain reaction assays for the detection of bacterial DNA.  
• Interferon release assays (IGRA’S) 
 
Treatment for Tuberculosis: 
         Standard "short" course treatment for TB consists of a six-month regimen (two months treatment with 
isoniazid, rifampin and pyrazinamide followed by four months of isoniazid and rifampin). Ethambutol or 
streptomycin may be added based on the drug sensitivity of the patient. Multiple drug therapy is adopted due 
to the rapid development of resistance to single drug regimen. For latent tuberculosis, the standard treatment 
of six to nine months of isoniazid alone is preferred. 
 
                                       Mechanism of action of the first line drug used in TB 
Current Knowledge about TB Research 
               Several strategies are now being adopted by the researchers for their discovery of new anti-
tuberculosis agents which includes the large scale screening of both natural and synthetic compounds, 
targeting the specificity of activity, which means the inhibiting of Tuberculosis bacillus but not the 
mammalian cells lead compounds are then optimizing and also attempts are made to optimize the anti-
tubercular activity of antibiotics used for the other infections. 
           Since the current diagnostic tools available to identify active tuberculosis are slow and unreliable, the 
development of newer diagnostic tools which are rapid and with improved reliability can be done as a part of 
the improvement of therapy. A major area of emphasis for further generation in the research to support their 
development of vaccines for the prevention of the tuberculosis infection. The ongoing efforts of the 
medicinal chemists will be surely be a greatest contribution to the community against tuberculosis. 
         An anti-microbial77 is a substance which kills or inhibits the growth of microorganisms such as 
bacteria, fungi or protozoans. Anti-microbial drugs either kill microbes or prevent the growth of the 
microbes. 
         The history of antimicrobials begins with the observations of Pasteur and Joubert, who discovered that 
one type of bacteria could prevent the growth of another. They did not know at that time the reason was one 
bacterium failed to grow, was that the other bacterium were producing an antibiotic. Ofcourse, in today’s 
common usage, the term antibiotic is used to almost any drug attempts to rid of your body of the bacterial 
infection. Antimicrobials include not just antibiotics, but synthetically formed compounds as well. 
        However, with the development of antimicrobials, microorganisms has adapted and become resistant to 
previous antimicrobial agents. The old antimicrobial technology were based either poisons or heavy metals, 
which may not have killed the microbes completely, allowing the microbes to survive, change, and become 
resistant to the poisons and/or heavy metals. 
       Antimicrobial nanotechnology is a recent addition to fight against disease causing organism, replacing 
heavy metals and toxins and may someother day to be a viable alternative. 
Mechanisms: 
        The mechanisms by which the microorganism exhibit resistance to the antimicrobials are, 
• Drug inactivation or modification; for example, enzymatic deactivation of penicillin G in some 
penicillin-resistant bacteria through the production of β-lactamases. 
• Alteration of target site: for example, alteration of PBP the binding target site of penicillins in MRSA 
and other penicillin-resistant bacteria. 
• Alteration of metabolic pathway; for example, some sulfonnamide resistant bacteria do not require 
para-aminobenzoic acid (PABA), it is an important precursor for the synthesis of folic acid and 
nucleic acids in bacteria inhibited by the sulphonamides, instead, like mammalian cells, which turn to 
using performed folic acids. 
• Reduced drug accumulation by decreasing drug permeability and/or increasing active efflux 
(pumping out) of these drugs across the cell surface. 
 
 
 Antimicrobial Resistance: 
        Antimicrobial resistance (AMR) is the resistance of a microorganism to an antimicrobial medicine to 
which it were previously sensitive. Resistant organisms (they include bacteria, viruses and some parasites) 
are able to withstand attack by antimicrobial medicines, such as antibiotics, antivirals and antimalarials. So 
that the standard treatments become ineffective and infections persist and may spread to others. AMR is a 
consequence of the use, particularly the misuse of antimicrobial medicines and develops when a 
microorganism mutates or acquires a resistant gene. 
         Bacteria78 are a large domain of prokaryotic microorganisms. The bacterial cells are about one tenth 
the sizes of the cells and are typically 0.5-5.0 micrometres in length. It is present in most habitats on earth, 
growing in soil, acidic hot springs, radioactive waste, water, and deep in the earth’s crust, as well as in the 
organic matter and the live bodies of plants and animals. There are typically 40 million bacterial cells in a 
gram of soil and a million bacterial cells in a millilitre of fresh water. Bacteria are vital in recycling 
nutrients, with many steps in nutrient cycle depending on these organisms such as the fixation of nitrogen 
from the atmosphere, Putrefaction.  
        Bacterial infections79, 80 may be treated with antibiotics, which are classified as bacteriocidal (kill 
bacteria), or bacteriostatic (prevent bacterial growth). There are many types of antibiotics and each class 
inhibits a process which is different in the pathogen from that found in the host. Antibiotics are used both in 
treating human disease and intensive farming to promote animal growth, where they may be contributing to 
the rapid development of antibiotic resistance to the bacterial population. 
Pathogenic bacteria81: 
        Bacteria form a parasitic association with other organisms, which are classed as pathogens. Bacteria 
that can cause disease are called pathogenic bacteria. Bacteria can cause diseases in humans in other 
animals, and also in plants. Some bacteria can only make one particular host ill, depending on the host 
specificity of the bacteria and some pathogenic bacteria have received disproportionate attention in the press, 
example; the flesh eating bacteria. There are major cause of human death and disease and the infections such 
as tetanus, typhoid fever, diphtheria, syphilis, cholera, foodborne illness and leprosy. A pathogenic cause of 
a known medical disease may only be discovered many years after, as were the case with Helicobacter pylori 
and Peptic ulcer disease. Each species of pathogen have a characteristic spectrum of interactions with its 
human hosts. The organisms such as staphylococcus or streptococcus, it can cause skin infections. 
       Yet these organisms are also a major part of the normal human flora and usually exist on the skin or 
nose without causing any disease at all. Other organisms which in variably can cause disease in humans, 
such as the rickettsia, that are obligate intercellular parasites which is able to grow and reproduce only 
within the cells of other organisms. 
 
             A Fungus82 is a member of a large group of eukaryotic organism which includes microorganisms 
such as yeasts, moulds and mushrooms. Fungi perform an essential role in the decomposition of organic 
matter and have fundamental roles in the nutrient cycling and exchange. Since 1940’s fungi was used for the 
production of antibiotics, and most recently, various enzymes produced by fungi which are used industrially 
and in detergents. Fungi can breakdown the manufactured materials and buildings. Losses of crops due to 
fungal diseases (e.g. rice blast disease) and food spoilage can have a large impact on human food supplies 
and local economics. 
Antibiotic Resistance: 
               Antibiotic resistance is the type of drug resistance, where a microorganism is able to survive 
exposure to an antibiotic. Many antibiotics resistance genes reside of plasmids, facilitating their transfer. If a 
bacterium carries several resistant genes which is called multidrug resistant. Any use of antibiotics can 
increase selective pressure in population of bacteria to allow the resistant bacteria to thrive and the 
susceptible bacteria to die off. As resistance towards antibiotics becomes more common and a greater need 
for alternative arises. 
 
             Cinnoline ring is a versatile lead molecule7 that has been investigated widely used in medicinal 
chemistry due to its important pharmacological activities. The nucleus gives out different derivatives with 
different biological activities8-34. This have been reported to exhibit anti-microbial, anti-tubercular, anti-
malarial, anti-hypertensive, anti-convulsant, neurological disorders, anti-depressant, anti-pyretic, analgesic, 
anxiolytics, anti-diabetic, anaesthetic, anti-thrombolytic, cardiotonic, anti-tumor, herbicidal, agrochemical 
insecticidal, etc. In the present study, it is envisaged to combine Cinnoline nucleus with Pyrazoline ring 
system and Sulfonamide compounds have important biological activities. 
          Cinnoline35 is 1,2-diazonaphthalene the nitrogenous organic base, obtained from certain complex 
diazole compounds, it is benzfused Pyridazine containing two nitrogen atoms at 1,2 position and its 
categorized under benzfused diazines class of heterocyclic compounds. Its isosteric relative to either 
Quinoline or Isoquinoline. Some of the Cinnolines have been screened and have received approval as 
bioactive drugs are under clinical trials. 
         Cinoxacin (Cinobac) 98 is an, Quinolone, is 1-ethyl-1, 4-dihydro-4-oxo-[1, 3] dioxolo [4, 5-g] 
Cinnoline-3-carboxylic acid and occurs at white or very light yellow needle shaped crystals. It is a synthetic 
antibacterial agent for oral administration used in urinary tract infections. It is available as 250-500mg 
capsules. 
 
CHEMISTRY OF CINNOLINES 
             Cinnolines are coming under benzodiazines36, 37. Cinnoline is benzo analogs of Pyridiazine, 
Phthalazine benzo Pyridiazine, 1, 2 diazonaphthalene. 
 
 
 
 
Other benzodiazines are, 
 
                               
 
Methods of synthesis of Cinnolines: 
            A diazo group38 attached to an aromatic ring can couple with an alkyl group in ortho position 
provided that the latter and is activated by an electronegative substituent. But since the activation does not 
extend beyond the α-carbon atom of the alkyl group coupling takes place at that position and a five-
membered Pyrazole ring is formed. In general, Six-membered rings are formed more easily than five-
membered ones. If an unsaturated chain of two or more carbon atoms takes place of the ortho-alkyl group, 
this chain is nucleophile at the ground state. And if the β-carbon atom acquiries a sufficient it may be 
substituted by an ortho diazonium ion so that a fused six membered ring containing two continuous nitrogen 
atoms are formed. 
 
  
             The substituents R & R’ are mainly responsible for activation of the β-carbon atom. The product are 
the derivates of benzo-1, 2-diazine, also named benzopyridazine or Cinnoline. Conditions suitable for 
Cinnoline formation are present in the diazo compounds. 
            Widman39 observed that a cold acid solution of diazotized 3-amino-4-propen-2-yl benzoic acid gives 
4-methylCinnoline-7-carboxylic acid as a result of intramolecular coupling. 
 
 
Borsche Reaction40: 
            This involves the diazotization of ortho-aminoacetophenones in aqueous medium which provides an 
easy access to Cinnolines. 
 
  
           The Cinnoline ring was first synthesized by Richter during the diazotization of ortho-amino-
Phenylpropionic acid and cyclization of the obtained arene diazonium salt. 
            Three main approaches41 for the synthesis of Cinnolines are using derivatives of arenediazonium 
salts, aryl hydrazones, and aryl hydrazines as precursors and also reductive methods for the synthesis of 
polycondensed derivatives of Cinnoline.    
ARYLHYDRAZONES AND ARYLHYDRAZINES AS PRECURSOR OF 
CINNOLINES42, 43 
          This approach is the most universal since it makes it possible to obtain derivatives of Cinnoline with 
the various types of substituent at various positions which includes in the methods of the Cinnoline system is 
formed at various positions of Pyridazine ring. As a rule, ring closure occurs during attack of the amino 
group at a CC, CO, or CN multiple bonds. An example of the production of Cinnoline through the formation 
of the N (2)-C (3) bond is the classical method for the synthesis of 3-hydroxyCinnolines the Neber-Bossel 
method. During the diazotization of (2-aminophenyl) hydroxyacetate and reduction of the diazonium salt the 
obtained hydrazine undergoes cyclization to 3-hydroxyCinnolines. When boiled in HCL substituents in the 
aromatic ring have an appreciable effect on the course of cyclization, and in the case of the unsubstituted and 
4-Chloro substituted ring the yields of the desired compounds are 60 and 70% respectively. 
 
              Hydrazones obtained from ortho-trifluoromethyl arylhydrazines44 and benzaldehydes undergo 
cyclization by the action of a base, forming a Pyridazine ring. The products in this case are 4-amino 3-aryl 
Cinnolines, and their yields amount to 60-90%. 
 
This approach was first described in 1956 by Barber and Co-workers. The formation of a Cinnoline ring 
with the participation of aryl hydrazones through the construction of a bond between the fourth carbon atom 
and the benzene ring can also be realized under the conditions of the Friedal-Crafts reaction45. Nowadays 
this method has been used for the synthesis of polycondensed derivatives of Cinnoline. 
CHEMICAL REACTIONS 
The chemical reactions of Cinnolines are, 
Nucleophilic substitution reaction46,47: 
                    Vigrous conditions are required for methoxylation of 3-Bromo, 3-ChloroCinnoline reacts with 
aqueous ammonia at 20 hr at 30oC to form the amination of Cinnoline. 
 
Electrophilic substitution reaction48, 49, 50: 
               The nitration of Cinnoline involves the conjugate acids formed by the addition of proton to the one 
of the nitrogen atom. 
 Halogenation51, 52: 
          4-HydroxyCinnoline is reacted with Phosphorous oxytrichloride and Pyridine to form 4-
ChloroCinnoline. 
 
Reduction53, 54, 55: 
          The 3-HydroxyCinnoline reacts with the reduction of lithium hydride to form 1, 2, 3, 4-tetrahydro 
Cinnoline. 
 
PYRAZOLE 
           Pyrazole131 was given to this class of compounds by Ludwig knorr in 1883. It is the class of simple 
aromatic ring organic compounds of the heterocyclic diazole series characterized by a 5-membered ring 
structure composed of three carbon atoms and two nitrogen atoms in adjacent positions, and to the 
unsubstituted parent compound.  
 
Method of Pyrazole: 
         Pyrazoles are produced synthetically through the reaction of α, β unsaturated aldehydes with hydrazine 
and subsequent dehydrogenation. 
 
      In medicine, derivatives of Pyrazoles are used for their analgesic, anti-inflammatory, anti-pyretic, anti-
arrhythmic, tranquilizing, muscle relaxing, psychonaleptic, anti-convulsant, monoamineoxidase (MOA) 
inhibiting, anti-diabetic and anti-bacterial activities. 
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AIM OF THE PRESENT WORK 
 
         Malaria56 is the most dreadful illness and widespread infectious disease because of its prevalence, 
virulence and drug resistance, having an overwhelming impact on public health in developing regions of the 
world. It affects more than 2400 million people, over 40% of the world population. Casual organism for 
malaria belongs to genus Plasmodium. Plasmodium falciparum is the main cause of severe clinical malaria 
and the World Health Organisation (WHO) has forecast an annual growth of 16% in malarial cases. As the 
parasites rapidly develop permanent resistance against the different subclasses of existing drugs, there is a 
great urge to develop new and effective drugs attacking crucial targets in the metabolism of the malarial 
pathogen. Malaria can be eliminated by proper drug therapy. 
    
       Mycobacterium tuberculosis62, the causative agent of tuberculosis (TB), is a tenacious and remarkably 
successful pathogen that has latently infected a one-third of the world population. It can be cured, the 
therapy takes at least 6-9 months and laborious and lengthy treatment brings with it dangers of non-
compliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the 
problem of mycobacterial persistence, prolonged therapy, and drug toxicity highlight the need to develop 
novel TB drugs that are active against drug resistant bacteria. 
 
      Microorganisms78, 79 like bacteria and fungi causes many infections like meningitis, ottis media, 
pneumonia, cholera, food poisoning, urinary tract infections, aspergillosis, candidoses, etc. Many of these 
diseases are fatal if untreated, and treatment has been complicated by the resistance of the microorganisms to 
the widely used drugs. To combat the problem of resistance newer drugs are needed. 
 
          The increasing emergence of drug resistance highlights the need to develop some novel active Anti-
malarial, Anti-tubercular and Anti-microbial drugs. 
 
         Cinnoline35 is, 1, 2-diazanaphtalene or benzo[c]-1, 2-diazine (Hantsch-Widmann system), it is a 
nitrogenous organic base, obtained from certain complex diazole compounds. It is a benzfused pyridazine 
containing two nitrogen atoms at 1, 2-position and it is categorized under benzfused diazines class of 
heterocyclic compounds. Its isosteric relative to either quinoline or isoquinoline. 
  
        Cinnoline ring is a versatile lead molecule7 that has been investigated widely in medicinal chemistry 
due to its important pharmacological activities8-34. It have been reported to exhibit anti-microbial, anti-
tubercular ,anti-cancer, anti-malarial, anti-hypertensive, anti-pyretic, anti-thrombolytic, analgesic, anti-
diabetic, anti-depressant, cardiotonic, anaesthetic, anxiolytic etc.  
 
                In medicine131, derivatives of Pyrazoles are used for their analgesic, anti-inflammatory, anti-
pyretic, anti-arrhythmic, tranquilizing, muscle relaxing, anti fungal, anti tubercular, psychonaleptic, anti-
convulsant, monoamineoxidase (MOA) inhibiting, anti-diabetic and anti-bacterial activities. 
 
         The Anti-malarial, Anti-tubercular, and Anti-microbial activity of Cinnolines and the well known 
biological importance of Sulfonamides, Pyrazole prompted us to substitute these into Cinnoline nucleus, 
hoping to get compounds with enhanced potency against Plasmodium protozoa, Mycobacterium, bacteria 
and fungus which may overcome the existing lacuna in the current treatment of these infectious diseases. 
  
The objectives of the present work can be summarized as follows: 
• Synthesis of some Novel potential derivatives of Cinnoline fused with Sulfonamide and Pyrazoline 
group. 
• Characterization of synthesized compounds by various analytical techniques like TLC, UV, IR NMR 
and Mass Spectral studies. 
• Screening for anti-malarial activity against Plasmodium falciparum by culturing Plasmodium 
faliciparum from infected human blood sample by using Candle Jar method. 
• Screening for anti-tubercular activity against Mycobacterium tuberculosis H37Rv by Resazurin Dye 
Reduction Assay method. 
• Screening for anti- bacterial activity against bacterial organisms like Micrococcus luteus, 
Staphylococcus aureus, Bacillus subtilis, Corynebacterium diphtheria, Bacillus linctus, Escherchia 
coli, Pseudomonas aureginosa, Rhodosporum rubrum, Vibrio cholera and Salmonella paratyphi by 
Disc diffusion method and determination of Minimum inhibitory concentration (MIC) by Serial 
dilution method.  
• Screening for anti-fungal activity against fungal organisms like Candida albicans, Streptomyces 
griseus, Aspergillus niger, Aspergillus fumigatus, Monascus ruber, by Disc diffusion method and 
determination of Minimum inhibitory concentration (MIC) by Serial dilution methods. 
 
  
 
 
 
 
 
 
 
                           
                    Experimental  
                                Work 
SYNTHESIS OF SOME NOVEL CINNOLINE DERIVATIVES87 
METHODOLOGY 
STEP1 
Preparation of diazonium salt [Diazotisation] 
        Sodium nitrite (7.4gm,0.1mol) dissolved in 26ml of water was added to a suspension of Sulfanilamide 
(10gm,0.1mol) in 1N HCl (200 ml), and the mixture was stirred for 1hr at 0-5˚C  and filtered to obtain the 
clear diazonium salt. 
STEP 2  
Preparation of Phenyl hydrazano acetyl acetone-4-Sulfonamide [Griess diazo reaction] 
        The diazonium salt obtained was then added to a well stirred solution of ethanol (30ml), water (500ml) 
and acetyl acetone (10.01gm, 0.1mol) at 0ºC with stirring. Sodim acetate was then added to keep the mixture 
alkaline to litmus after 3 hour stirring at 0ºC the crude product was filtered, washed with water and air dried. 
Recrystallisation from ethanol afforded yellow needles of purified Phenyl hydrazano acetyl acetone-4-
Sulfonamide. 
     The purity of product obtained was established by single spot on the TLC plate. The solvent system used 
was Benzene: Ethyl acetate (8: 2). Melting point was determined and uncorrected. 
STEP 3 
Preparation of 4-methyl 3-acetyl Cinnoline 6-Sulfonamide [Intramolecular cyclization] 
         The Phenyl hydrazano acetyl acetone-4-Sulfonamide (10g, 0.05mol) was added to the 
Polyphosphoric acid (16gm, 7.216 ml, 0.03mol) in small lots over 30 mins while maintaining the 
temperature between 60-650C. The reaction was maintained for an additional 2 hour and monitored by TLC. 
After the completion of reaction, icecold water (200 ml) was added carefully to decompose the black residue 
at 0-50C. The product was then extracted with ethyl acetate. Ethyl acetate layer was then treated with 
Charcoal and concentrated to get the crude product as a brownish black residue. Recrystallisation from 
methanol to obtained as light yellow crystals of 4-methyl 3-acetyl Cinnoline 6-Sulfonamide. 
         The purity of the product was confirmed by a single spot on the TLC plate and solvent system used 
was Benzene: Ethyl acetate (8:2). Melting point was determined and uncorrected. 
STEP 4 
Preparation of 1-(4-methyl Cinnoline-3-yl)-3-(substituted phenyl) prop-2-en-1-one 6-
Sulfonamide [Cinnoline based chalcone] 
       The product obtained from step 3(2.03gm,0.01mol) and aromatic aldehyde in same ratio (0.01mol) in 
ethanol (50ml) was cooled at 0-5oC and added (5-10ml) 40% NaOH solution till precipitated and washed 
with ice water. Few drops N/20 dilute HCl was added for complete precipitation and filtered washed with ice 
water and recystallised from alcohol to afford the compound (CN-1 -11). 
       The purity of the product was confirmed by a single spot on the TLC plate and solvent system used was 
Benzene: Ethyl acetate (8:2). Melting point was determined and uncorrected. 
STEP 5 
Preparation of 4-methyl-3-[5-(substituted phenyl)-4, 5-dihydro-1H-Pyrazol-3-yl] 
Cinnoline-6-Sulfonamide [Intermolecular cyclization] 
        The compound CN-1-11 (0.01mol) in 20ml acetic acid was taken and hydrazine hydrate (0.01mol) was 
added to it and refluxed for 10 hour. The contents were poured into ice, filtered and the product isolated, 
crystallized from ethanol to afford the compound (CN-1a-11a). 
        The purity of the product was confirmed by a single spot on the TLC plate and solvent system used was 
Benzene: Ethyl acetate (8:2). Melting point was determined and uncorrected. 
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1 CN-1a 
 
2 CN-2a 
 
3 CN-3a 
 
4 CN-4a 
 
5 CN-5a 
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8 CN-8a 
 
9 CN-9a 
 
10 CN-10a 
 
11 CN-11a 
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ANTI MALARIAL SCREENING 
CANDLE JAR METHOD121, 122,123 
PROCEDURE 
Preparation of Serum: 
• Fresh human whole blood (preferably o+ or A+) was collected in a blood collection bags without 
anticoagulant. And (before clotting occurs) the blood was transferred to the sterile 50ml centrifuge 
tubes. (In a laminar flow cabinet) 
• The blood was stored overnight at 4oC to allow clotting. 
• The serum and erythrocytes was fractionated by centrifugation. (2500 rpm for 30mins at room 
temperature) 
• The serum was then transferred under sterile conditions to new sterile 50ml tubes. 
• The serum was then heat inactivated by incubation in a water bath for 20mins at 65oC. 
• The serum was then stored at -20oC in the 50ml sterile tubes. 
P.falciparum culture: Media and Buffers (Serum): 
The medium used for culturing of Plasmodium falciparum was prepared as follows: 
Ingredients used 
 S.NO                   INGREDIENTS          QUANTITY 
    1 RPMI-1640(sigma)               10.4g 
    2 HEPES (sigma, cell culture tested)               5.94g 
    3 D-glucose (sigma, cell culture tested)               4.0g 
    4 Hypoxanthine(sigma, cell culture tested)               44mg 
    5 Gentamycin               0.4ml 
    6 Distilled water             1000ml 
 
             The accurately weighed quantities of the above ingredients were transferred into the conical flask, mixed 
well and leave for 30 minute at room temperature. Add 36ml of 5% NaHCO3 solution was added to the medium to 
buffer the solution at pH of 7.4. The solution was filtered using a sterile Millipore filter (0.22mm). Filtered 
solution was divided into two halfs. Transferred half to the 500ml medium bottle and stored at 4oC (wash 
medium). 50ml human serum was added to the other half and transferred to a 500ml medium bottle and stored at 
40C(culture medium). 
Preparation of Erythrocytes: 
• Erythrocytes were collected in a 10ml vacutainer (vacutest) tubes with anticoagulant (EDTA purple). 
• The bloods were transferred under sterile conditions to the sterile 10ml centrifuge tube. 
• It was centrifuged to separate the cells and serum (2500 rpm for 5mins at room temperature). 
• The serum and “Buffy-coat” was aspirated using a Pasteur pipette fixed to the vacuum line. 
• The volume was then supplemented to 10ml with “wash medium” and mixed well. 
• The cells were centrifuged (2500 rpm for 5mins at room temperature). 
• Steps 4 to 6 were repeated another two times. 
• The washed erythrocytes was resuspended in wash medium and stored at 4oC. 
Cultivation of Parasites: 
             Preheat the culture medium by placing it in the 37oC water bath or in the incubator. O.5ml of culture 
medium, 20µl of washed erythrocytes and 20µl of P.falciparum infected human blood were placed in 96 well plates. 
The well plates were placed in a candle jar and incubated at 37oC for 24hrs. Parasite counts were made on giemsa 
stained thin smears. 
 Preparation of thin smears: 
• A small amount of erythrocytes were removed using a Pasteur pipette and placed on a microscopic 
slide. The second slide was placed on the first and moves it back into the drop, spreading it. The 
second slide was then moved forward, smearing a film of blood across the first slide. 
• The smear was allowed to dry and then it was fixed with methanol. 
• The methanol was discarded and the slide was covered with giemsa stained solution for 3 to 5 
minutes to stain. (The giemsa solution consists of approximately 0.5ml phosphate buffer and 10-20 
drops of concentrated giemsa stock solution). Then rinsed with water and allowed it to dry, where 
after it was studied microscopically (100x). 
• Parasitemia were counted by counting both uninfected and parasite infected erythrocytes. 
• Expressing the parasite count as a percentage of infected erythrocytes as per total erythrocyte count. 
 
 
 
Interpretation of microscopic slides:  
 Different stages of malaria parasite in the red blood cells interpreted. 
Uninfected erythrocytes 
 
Infected erythrocytes 
                   Different stages of the malarial parasite in the red blood cells. 
 Ring: 
 
Early Trophozoite:  
 
Trophozoite: 
 
 
 
 
Transition Stage: 
 
Anti-Plasmodial activity of the synthesized compounds: 
              Various concentrations of the synthesized compounds and standard drug pyremethamine (20,40,60,80 
µg/ml) in DMSO, was added to the well plates containing 0.5ml of culture medium, 20 µl of washed erythrocytes and 
20 µl of P.falciparum infected human blood. Well plates were placed in the candle jar and incubated at 37oC for 24hrs. 
Parasite count were made on the giemsa stained thin smears prepared at different time intervals (24, 48, 72 hrs). And 
in-vitro anti-plasmodial activity of the synthesized compounds was determined by calculating inhibitory concentration 
percentage (IC50). Percentage can be calculated using the formula, 
IC50= No of parasitemia in control – No of parasitemia in treated × 100 
No of parasitemia in control 
 
 
 
 
 
 
 
 
 
 
 
 
ANTI-TUBERCULAR SCREENING124 
RESAZURIN DYE REDUCTION ASSAY 
           Resazurin is an oxidation reduction indicator used for the evaluation of cell growth, particularly in various 
cytotoxicity assays. It is a blue non fluorescent and non toxic dye that becomes pink and fluorescent when reduced to 
resorufin by oxide reductive within viable cells. 
PROCEDURE: 
                Mycobacterium tuberculosis H37Rv was grown in Middle brook 7H9 broth (Difco, USA) containing 
0.05% Tween 80, 0.05% Glycerol and 5% OADC supplement (Becton Dickinson, USA). The culture was grown till 
log-phase and was diluted to McFarland 1 standard with the same medium. From these 50 micro litres was added to 
450 micro litre of fresh medium in 2ml eppendorf tubes. Stock solution of the test compounds was prepared in 
DMF/DMSO. And the compounds were tested at 1, 10 & 100 micro gram per ml concentrations. And Rifampacin 
1µg/ml was used as positive control, control tubes had the same volume of DMF/DMSO without any compound. After 
incubation at 37oC for 7 days, 30 microlitre of 0.01% resazurin (Sigma, St. Louis. MO. USA) in water was added to 
each well. Resazurin, a redox dye, is blue in the oxidized state and turns pink when reduced by growth of viable cells. 
The control tubes showed change of colour from blue to pink after 24 hours at 37oC. Compounds in the well which 
remained blue were considered to inhibitory to M.tuberculosis at their respective concentrations. 
  
           
                                    
 
 
 
 
 
 
 
 
 
ANTI-BACTERIAL SCREENING 
DISC DIFFUSION METHOD125, 126,127 
PROCEDURE 
Preparation of Muller Hinton Agar Medium: 
                Composition of Muller Hinton Agar Medium 
 S.NO                INGREDIENTS      QUANTITY 
   1                 Beef extract            10g 
   2          Casein acid hydrosylate            17.5g 
   3                  Starch            1.5g 
   4                   Agar            20g 
   5             Distilled water           1000ml 
 
                Specified amount of Muller Hinton Agar was taken along with 1000ml of distilled water in a conical flask 
and then heated in a steam bath to dissolve. The pH was maintained at 7.6 ± 0.2 and sterilized in an autoclave at 15 lb 
pressure, 120oC for 15 minutes. The sterile medium was poured into the sterile Petri dish and allowed to solidify. 
Preparation of plates: 
                Muller Hinton agar medium were prepared and transferred into the sterile Petri plates aseptically (thickness 
of 5-6mm). The plates were allowed to dry at room temperature. The plates were inverted to prevent condensate 
falling on the agar surface. The layers of the medium are uniform in thickness, is done by placing the plates on the 
levelled surface. Standardized bacterial inoculums of Micrococcus luteus, Staphylococcus aureus, Bacillus subtilis, 
Corynebacterium diphtheria, Bacillus linctus, Escherichia coli, Pseudomonas aureginosa, Rhodosporum rubrum, 
Vibrio cholera, Salmonella paratyphi were applied to the plates and spreaded uniformly over the surface of the 
medium by using a sterile non- absorbent cotton swab and finally the swab was passed around the edge of the medium. 
The inoculated plates were closed with the lid and allowed to dry at room temperature. The sample impregnated discs 
(100µg/disc) in dimethyl sulphoxide and standard ciprofloxacin 100µg disc were placed on the inoculated agar 
medium. All petriplates were incubated at 37oC for 24 hrs. After the incubation produced by the sample were 
measured. The anti-bacterial activity were evaluated by measuring zone if inhibition in mm. 
 
 
 
Determination of Minimum Inhibitory Concentration of Synthesized compounds (MIC) 
by Serial dilution Method128: 
• The serial dilution of known concentration of the compound solution was made from the stock (10 
µg/ ml) by using Muller Hinton broth using the method described below. 
• The test tubes were labelled 1 to 8 and 1ml of Muller Hinton broth were added to the first 5 tubes and 
8th tube, then added 0.5ml Muller Hinton broth to 6th and 7th tubes. 
• One ml of different synthesized compounds was added to the 1st tube, mixed well and transfer 1ml 
serially upto tube 5. From the 5th tube transfer 1ml to 6th tube. Mixed and transfer 0.5ml to the 7th 
tube, 1 to 7 contains 1ml diluted synthesized compounds. 
• The 8th tube was the control. 
• With a standardized micro pipette, add a drop of the diluted broth culture approximately 0.01ml of 
the test organism to all test tubes, including the control, gently mixed and incubated at 37oC for 
24hrs. 
• The highest dilution of particular compounds showing no turbidity was observed and recorded. This 
was taken as the end point, and this dilution was considered to contain the concentration of drug 
equivalent to MIC. 
  
 
 
 
 
 
 
 
 
 
 
ANTI-FUNGAL SCREENING 
DISC DIFFUSION METHOD129, 130 
PROCEDURE 
Preparation of Sabourands dextrose broth: 
           Composition of Sabourands dextrose broth 
S.NO   INGREDIENTS     QUANTITY 
   1       Dextrose           40g 
   2       Peptone           10g 
   3        Water         1000ml 
 
               Specified amount of dextrose and peptone was taken along with 1000ml of distilled water in a conical flask 
and heated in a steam bath to dissolve. The pH was maintained at 7.6 ± 0.2 and sterilized in an autoclave at 15 lb 
pressure, 120oC for 15 minutes. The sterile medium was poured into the sterile Petri dish and allowed to solidify. 
Preparation of plates: 
            Sabourands dextrose broth medium were prepared and transferred into the sterile Petri plates aseptically 
(thickness of 5-6mm). The plates were allowed to dry at room temp. The plates were inverted to prevent condensate 
falling on the agar surface. The layers of the medium was uniform in thickness, is done by placing the plates on a 
levelled surface. Standardized fungal inoculums of Candida albicans, Streptomyces griseus, Aspergillus niger, 
Aspergillus fumigatus, Monascus ruber were applied to the plates and spreaded uniformly over the surface of the 
medium by using a sterile nson-absorbent cotton swab and finally the swab was passed around the edge of the 
medium. The inoculated plates were closed with the lid and allowed to dry at room temperature. The sample 
impregnated discs (100µg/disc) in dimethyl sulphoxide and standard Clotrimazole 100µg/disc were placed on the 
inoculated agar medium. All petriplates were incubated at 27oC – 28oC for 48 hrs. After the incubation diameter of 
zone of inhibition produced by the sample were measured. 
 
 
 
 
Determination of Minimum Inhibitory Concentration of the Synthesized Compounds 
(MIC) by serial dilution Method: 
• The serial dilution of known concentration of compound solution was from the stock (10 µg/ml) by 
using Sabourands dextrose broth using the method described below. 
• The test tubes were labelled 1 to 8 and 1ml of Sabourands dextrose broth were added to the first 5 
tubes and 8th tube, then added 0.5ml of Sabourands dextrose broth to 6th and 7th tube. 
• One ml of different synthesized compounds was added to the 1st tube, mixed well and transfer 1ml 
serially upto tube 5. From the 5th tube transfer 1ml to 6th tube. Mixed and transfer o.5ml to the 7th 
tube. Each tube, 1 to 7 contains 1ml diluted synthesized compounds. 
• The 8th tube was the control. 
• With a standardized micro pipette, add a drop of the diluted broth culture approximately 0.01ml of 
the test organism to all test tubes, including the control, gently mixed and incubated at 26-28oC for 
48 hrs. 
• The highest dilution of particular compounds showing no turbidity was observed and recorded. This 
was taken as the end point, and this dilution was considered to contain the concentration of drug 
equivalent to MIC.   
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                            RESULTS AND DISCUSSION 
Table 1 .PHYSICO CHEMICAL PARAMETERS OF SYNTHESIZED DERIVATIVES 
*Mobile phase – benzene: ethyl acetate (8:2) 
                                                                                                                  
 
Sl.
No 
Compound  
code 
Molecular 
formula 
Molecular 
weight      
(g) 
Percentage
yield (%) 
Colour Solubility Melting 
Point 
(0C) 
Rf 
value
* 
1 CN-I C11H11N3O3S 265.29 76% Brownish 
yellow 
DMSO 85oC 0.42 
2 CN-1a C18H16N6O4S 412.42 92.5% Yellow DMSO 82oC  0.68 
3 CN-2a C18H17N5O3S 388.42 86.1% Yellow DMSO 110oC  0.72 
4 CN-3a C18H16N5O2S 366.42 87.2% Yellow DMSO 85oC 0.71
5 CN-4a C19H19N5O3S 397.45 90.7% Yellow DMSO 87oC  0.63 
6 CN-5a C19H19N5O4S 413.45 92.2% Yellow DMSO 82oC  0.52 
7 CN-6a C20H19N5O2S 393.46 86.1% Golden 
brown 
DMSO 80oC 0.67
8 CN-7a C20H22N6O2S 410.49 91.4% Yellow DMSO 210oC  0.75 
9 CN-8a C18H16FN5O2S 385.42 76.2% Yellow DMSO 92oC 0.62
10 CN-9a C18H16ClN5O2S 401.87 82.4% Yellow DMSO 85oC  0.66 
11 CN-10a C18H16ClN5O2S 401.87 74.2% Brownish 
yellow 
DMSO 87oC  0.56 
12 CN-11a C18H16N6O4S 412.42 89.5% Yellow DMSO 112oC 0.58
ANTI-MALARIAL SCREENING 
CANDLE JAR METHOD 
Table 3: In vitro anti Plasmodial activity of synthesized compounds against Plasmodium falciparum. 
S.No Compound 
Code 
IC50 Values (%) 
20 
 (µg/ml) 
40           
(µg/ml) 
60 
(µg/ml) 
80  
(µg/ml) 
1 Pyremethamine 72.30 80.15 87.69 95.32 
2 CN-1a 59.23 66.92 74.61 82.30 
3 CN-2a 46.15 51.53 66.92 72.30 
4 CN-3a 36.15 46.15 53.84 61.53 
5 CN-4a 49.23 56.92 64.61 72.30 
6 CN-5a 69.23 76.92 84.61 87.69 
7 CN-6a 30.76 38.46 43.84 50.00 
8 CN-7a 41.53 46.15 57.69 61.53 
9 CN-8a 52.30 61.53 69.23 76.92 
10 CN-9a 27.69 42.30 51.53 56.92 
11 CN-10a 33.84 43.84 61.53 72.30 
12 CN-11a 61.53 69.23 76.92 84.61 
 
 
          
 
 
ANTI-TUBERCULAR SCREENING 
RESAZURIN DYE REDUCTION ASSAY 
Table 4: In vitro Anti -mycobacterial activity of the synthesized compounds against Mycobacterium 
tuberculosis H37RV. 
                 
 
                                           
Control   - Drug free control 
Rifampicin 1μg/ml – Positive drug control  
 
 
 
 
S.No Compound 
code 
Concentration of synthesized compounds 
1μg/ml 10μg/ml 100μg/ml 
1 CN-5a N N P 
2 CN-2a N N N 
3 RIF P P P 
 
       P = Inhibition 
       N = No Inhibition 
ANTI-BACTERIAL SCREENING 
DISC DIFFUSION METHOD 
Table 5: Anti-bacterial activity of the synthesized compounds 
S.
N 
       Micro 
  organisms 
 
                                    Zone of Inhibition (in mm) 
                                     Compounds (100µg/disc) 
  
CN 
1a 
 
CN 
2a 
 
CN 
3a 
 
CN 
4a 
 
CN 
5a 
 
CN 
6a 
 
CN 
7a 
 
CN 
8a 
 
CN 
9a 
 
CN 
10a 
 
CN 
11a 
      
 Std
   *  
1 Micrococcus 
Luteus 
10 8 9 9 10 9 9 10 11 11 10 18 
2 Staphylococcus 
Aureus 
11 10 12 8 11 12 12 11 10 11 11 17 
3 Bacillus 
Subtilis 
9 9 10 9 9 10 10 9 9 9 10 15 
4 Corynebacterim 
Diphtheria 
9 10 10 8 9 8 8 10 10 10 9 16 
5 Bacillus 
Linctus 
8 10 8 10 10 11 11 11 9 9 11 18 
6 Escherichia 
Coli 
11 10 12 11 10 11 11 11 13 15 12 16 
7 Pseudomonas 
aureginosa 
9 10 10 8 11 10 9 11 10 8 11 15 
8 Rhodosporum 
Rubrum 
11 12 12 11 11 12 12 14 13 14 12 15 
9 Vibrio cholera 9 11 11 10 14 11 13 11 14 10 15 18 
10 Salmonella 
Paratyphi 
11 11 13 11 10 9 13 11 10 9 11 15 
*- Ciprofloxacin 
 
 
                                           
 
 
ANTI-BACTERIAL SCREENING 
               
 
Micrococcus luteus 
 
 
Staphylococcus aureus 
 
 
Bacillus subtilis 
 
 
 
  
Corynebacterium diphtheria 
 
 
Bacillus linctus 
 
 
Escherichia coli 
 
 
 
  
 
Pseudomonas aureginosa 
 
 
Rhodosporum rubrum 
 
 
Vibrio cholerae 
          
 
 
 
                  
 
Salmonella paratyphi 
                
 
 
               
     
 
 
 
               
 
 
                   
 
                
 
 
SERIAL DILUTION METHOD 
Table 6: MIC values of the synthesized compounds. 
S 
N 
Micro 
organisms 
MIC VALUES (µg/ml) 
CN 
1a 
CN 
2a 
CN 
3a 
CN 
4a 
CN 
5a 
CN 
6a 
CN 
7a 
CN 
8a 
CN 
9a 
CN 
10a 
CN 
11a 
Std* 
1 M.luteus 1.2 5 2.5 2.5 1.2 2.5 2.5 1.2 1.2 2.5 1.2 1.2 
2 S.aureus 1.2 2.5 1.2 5 2.5 1.2 1.2 2.5 2.5 2.5 1.2 1.2 
3 B.subtilis 5 5 2.5 2.5 2.5 2.5 1.2 1.2 2.5 2.5 1.2 1.2 
4 C.diphtheriae 2.5 1.2 1.2 5 2.5 5 5 1.2 1.2 1.2 2.5 1.2 
5 B.linctus 5 2.5 5 2.5 2.5 2.5 1.2 1.2 2.5 2.5 1.2 1.2 
6 E.coli 1.2 2.5 1.2 2.5 1.2 5 1.2 1.2 1.2 2.5 2.5 1.2 
7 P.aureginosa 2.5 2.5 1.2 2.5 1.2 2.5 2.5 2.5 1.2 1.2 2.5 1.2 
8 R.rubrum 5 2.5 2.5 5 2.5 1.2 2.5 1.2 2.5 2.5 1.2 1.2 
9 V.cholerae 5 2.5 2.5 5 1.2 2.5 1.2 2.5 1.2 2.5 1.2 1.2 
10 S.paratyphi 2.5 2.5 1.2 2.5 2.5 5 1.2 2.5 2.5 2.5 2.5 1.2 
*-Ciprofloxacin 
 
 
 
                  
 
 
                                     
 
ANTI-FUNGAL SCREENING 
DISC DIFFUSION METHOD 
Table 7: Anti-fungal activity of the synthesized compounds 
S.
N 
Micro 
organisms 
Zone of inhibition (in mm) 
Compound (100 µg/disc) 
CN 
1a 
CN 
2a 
CN
3a 
CN
4a 
CN
5a 
CN
6a 
CN
7a 
CN
8a 
CN 
9a 
CN 
10a 
CN 
11a 
Std* 
1 Candida 
albicans 
10 9 9 9 11 8 8 10 10 11 9 11 
2 Streptomyces 
griseus 
10 7 8 8 9 6 6 7 8 8 9 10 
3 Aspergillus 
niger 
9 9 9 8 10 9 11 10 9 9 8 11 
4 Aspergillus 
fumigalis 
8 8 7 7 9 7 7 8 8 7 6 9 
5 Monascus 
ruber 
8 7 7 6 8 8 6 7 7 8 8 9 
*- Clotrimazole  
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Streptomyces griseus 
 
 
Aspergillus niger 
 
 
  
 
Aspergillus fumigatus 
 
 
Monascus ruber 
 
 
 
 
 
 
 
 
 
 
SERIAL DILUTION METHOD 
Table 8: MIC Values of the synthesized compounds 
S.N Micro 
organisms 
MIC VALUES (µg/ml) 
CN 
1a 
CN 
2a 
CN 
3a 
CN 
4a 
 
CN 
5a 
CN 
6a 
CN 
7a 
CN 
8a 
CN 
9a 
CN 
10a 
CN 
11a 
1 Candida 
albicans 
2.5 1.2 2.5 2.5 2.5 5 5 2.5 2.5 2.5 1.2 
2 Streptomyces 
griseus 
1.2 2.5 2.5 2.5 2.5 5 2.5 2.5 5 2.5 1.2 
3 Aspergillus 
niger 
 
2.5 2.5 2.5 5 2.5 1.2 1.2 2.5 2.5 2.5 2.5 
4 Aspergillus 
fumigatus 
5 5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 5 1.2 
5 Monascus 
ruber 
2.5 2.5 2.5 2.5 2.5 1.2 1.2 2.5 5.0 2.5 2.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULT AND DISCUSSION 
            Provoked by the biological activity of the Cinnoline and in view of ongoing search for the most 
potent anti-malarial, anti-tubercular and anti-microbial agent, some novel 3, 7 Di substituted derivatives of 
Cinnoline have been synthesized and their anti-malarial, anti-tubercular and anti-microbial activity studied. 
The synthesis of designed Cinnoline analogues involves a five step procedure from a commercially 
available starting material 
Step 1: This step involves diazotisation of Sulphanilamide using Sodium nitrite in Hcl at a temp at 0-5oC to 
form diazonium chloride salt of Sulphanilamide (primary aromatic amine) in 95% yield. 
Step 2: This step involves Griess diazo reaction as the formed diazonium chloride salt of Sulphanilamide 
reacts with acetyl acetone and ethanol to form a keto group of Phenyl hydrazano acetyl acetone-4-
sulfonamide further it tautomerised to give the enol form, in 92% yield. 
Step 3: This step involves intramolecular cyclization of enol form of Phenyl hydrazano acetyl acetone-4- 
Sulfonamide by using Polyphosphoric acid as a cyclising agent at a temp of 60-65oC, in 76% yield. 
Step 4: This step involves the attack of methyl proton in the acetyl group by a base (40% NaOH) which 
results in the formation of carbanion. It reacts with substituted aromatic aldehydes which undergoes 
protonation by using ethanol to form Cinnoline based chalcones (CN-1-CN-11), in 82% yield. 
Step 5: This step involves intermolecular cyclization of Cinnoline based chalcones by reaction with 
hydrazine hydrate and acetic acid to form 4-methyl-3-[5-(substituted phenyl)-4,5-dihydro-1H-Pyrazol-3-
yl]cinnoline-6-Sulfonamide (CN-1a – CN-11a) by losing a water molecule, the yield was found to be 86%. 
          All the derivatives of Cinnolines were obtained with good yield. The percentage yield was found to be 
in the range of 74% - 92%.  
 
 
 
 
 
 
CHARACTERIZATION OF SYNTHEZISED COMPOUNDS 
The physical parameters like, molecular weight, solubility, melting point, and Rf of the synthesized 
compounds were determined. 
The melting points of the synthesized compounds determined and were uncorrected, and melting 
range was found to be between, 80-2050C 
The purity of the synthesized compounds was established by single spot on the TLC Plate and all the 
compounds found to be pure.  
  The structures of the synthesized compounds were confirmed by IR, NMR, and mass spectral 
analysis.  
IR Spectrum of the synthesized compounds showed the characteristic absorption band at 1503.24  
cm-1, 681.713cm-1, 1582.31cm-1 arising from stretching vibration of bands (C=N,C-S,C=C respectively), 
1530.24cm-1, 1401.03cm-1 due to NO2 stretching, C-Cl stretching, 680.749cm-1, 810.17 cm-1, 750cm-1 due to 
the substitution of benzene ring (O,P,M-substituted benzene), due to 3200cm-1 of R2NH  confirms the 
chemical structure of the compounds synthesized. 
 PMR spectra of the synthesized Cinnoline derivatives shows 4 aromatic protons as a multiplet in 
8.21-8.63 ppm, 2 Protons of amino group appeared at 2.0 ppm as a single, and  3 Protons of methyl group 
appeared as a singlet in 2.35-2.55 ppm, 4 protons of aromatic group appeared as a multiplet in 6.68-6.95 
ppm. Thus the proton magnetic spectrum of the compound was in full agreement with its molecular formula, 
with regard to proton count and the chemical shift also. 
  The Mass Spectral analysis of the synthesized compounds CN-I and CN-1a was performed, and the 
mass spectrum of the compound was in agreement with its molecular weight. 
 
 
 
 
                                         
BIOLOGICAL SCREENING 
ANTI-MALARIAL ACTIVITY: 
The anti-malarial studies was carried out with all synthesized Cinnoline derivatives in the 
concentration of 20µg/ml, 40µg/ml, 60µg/ml, 80µg/ml in DMSO against Plasmodium falciparum by using 
Candle jar method. Pyremethamine of same concentrations were used as a standard. The anti-malarial 
activities of the compounds were evaluated by estimation of percentage of inhibition of parasitemia at 
different concentration. It could be seen that these newly synthesized derivatives of Cinnoline exhibit 
moderate to good anti-malarial activity. Out of the compounds synthesized, CN-5a was most potent which 
exhibit 87% inhibition at 80µg/ml concentration. Other derivatives,which also showed inhibition more than 
50% respectively. 
ANTI -MYCOBACTERIAL ACTIVITY 
The synthesized compounds CN-2a and CN-5a were tested for activity against Mycobacterium 
tuberculosis H37Rv using Resazurin assay method at the concentration of 1µg/ml, 10µg/ml and 100µg/ml in 
DMSO.  Rifampicin 1µg/ml was used as a standard. The anti-mycobacterial activity of the synthesized 
compounds was evaluated by the change in colour of resazurin from Pink to blue by Oxido reductase with in 
viable cell. Among these two compounds, compound CN-5a inhibited the growth of Mycobacterium at 
100µg/ml. 
ANTI-BACTERIAL ACTIVITY 
The antibacterial studies were carried out with all the synthesized Cinnoline derivatives against gram 
positive and gram negative bacteria. It could be seen that these newly synthesized derivatives of Cinnoline 
exhibit moderate to good anti-bacterial activity. Out of the compounds synthesized, CN-11a, CN-9a, CN-5a 
was most potent with zone of inhibition against Rhodosporum rubrum, Vibrio cholera and Escherichia coli.  
The MIC of the synthesized compounds against Micrococcus luteus, Staphylococcus aureus, Bacillus 
subtilis, Corynebacterium diphtheria, Bacillus linctus, Escherchia coli, Pseudomonas aureginosa, 
Rhodosporum rubrum, Vibrio cholera and Salmonella paratyphi was determined by serial dilution method, 
was found to be in the range of 1.2-2.5µg/ml. 
 
 
ANTI- FUNGAL ACTIVITY 
Evaluation of the results from anti-fungal studies showed that synthesised Cinnoline derivatives 
exhibits moderate to good anti-fungal activity against Candida albicans Aspergillus fumigatus, Streptomyces 
griseus, Aspergillus niger, Aspergillus fumigalis, Monascus ruber with zone of inhibition was found to be in 
the range of (6-11mm). Out of the compounds, CN-5a, CN-7a, CN-11a were showed good activity against 
Candida albicans, Streptomyces griseus, with zone of inhibition was found to be in the range of 11mm. 
             The MIC of the synthesized compounds against Candida albicans Aspergillus fumigalis, 
Streptomyces griseus, Aspergillus niger, Aspergillus fumigalis, Monascus ruber was determined by serial 
diluton method, was found to be in the range of 1.2-2.5µg/ml. 
            All the synthesized compounds have showed good Anti-malarial, Anti-microbial activity and 
compound CN-5a shown Anti-tubercular activity, due to the incorporation of Sulfanamido and Pyrazole 
groups into Cinnoline nucleus. Out of these synthesized compounds CN-5a was found to be a promising 
candidate which exhibits Anti-malarial, Anti-tubercular and Anti-microbial activities due to the synergistic 
action of the substituents such as methoxy (OCH3) and hydroxyl (OH) group in CN-5a along with 
incorporation of Sulfanamido and Pyrazole in Cinnoline nucleus. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
                      Conclusion 
 
CONCLUSION 
      In Summary, some novel substituted Cinnoline derivatives have been synthesized and evaluated for its 
anti-malarial, anti-tubercular and anti-microbial activity. All derivatives demonstrated significant anti-
malarial, anti-tubercular and anti-microbial activity amongst, compound CN-5a was found to be most potent 
compound with promising activity against resistant strains of Plasmodium falciparum, Mycobacterium 
tuberculosis H37Rv, bacteria and fungus. 
       Taking into account the significant activities of the examined compounds, it is believed that further 
optimization of these identified chemical leads can probably lead to the development of more active 
molecules. Further studies on its possible mechanism and in vivo trials in experimental animals to broaden 
their pharmacological assessment, may provide a new analogue that can overcome drug resistance, 
prolonged treatment, complex drug regimen and side effects involved in the treatment of infectious diseases. 
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